Oncolytic virus-mediated immunotherapy: A combinatorial approach for cancer treatment

Journal of Clinical Oncology

Volumn 33, Issue 25, 2015, Pages 2812-2814

  Lawler, Sean E ^a   Chiocca, E Antonio ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TALIMOGENE LAHERPAREPVEC; ANTINEOPLASTIC AGENT; ONCOLYTIC VIRUS;

CANCER IMMUNOTHERAPY; CANCER PATIENT; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; MALIGNANT NEOPLASTIC DISEASE; NOTE; ONCOLYTIC VIROTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; VIRUS REPLICATION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HERPES SIMPLEX VIRUS 1; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; ONCOLYTIC VIRUSES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84941353918     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.5244     Document Type: Note

References (14)

1. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264, 2012
2. Rosenberg SA, Restifo NP: Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62-68, 2015
3. Chiocca EA: Oncolytic viruses. Nat Rev Cancer 2:938-950, 2002
4. Russell SJ, Peng KW, Bell JC: Oncolytic virotherapy. Nat Biotechnol 30:658-670, 2012
5. Chiocca EA, Rabkin SD: Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295-300, 2014
6. Andtbacka RH, Kaufman HL, Collichio F, et al: Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol [epub ahead of print on May 26, 2015]
7. Koppala AR, Nathan VL: FDA panel recommends approval for Amgen's skin cancer immunotherapy. Reuters, Markets, April 29, 2015. http://www.reuters.com/article/2015/04/29/amgen-fda-idUSL4N0XQ5Y020150429
8. Hu JC, Coffin RS, Davis CJ: A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12:6737-6747, 2006
9. Martuza RL, Malick A, Markert J.M., et al: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856, 1991
10. Coffin RS: US Patent No. 7,063,835. United States Patent and Trademark Office. http://patents.com/us-7063835.html
11. Ikeda K, Wakimoto H, Ichikawa T., et al: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 74:4765-4775, 2000
12. Kaufman HL, Kim DW, DeRaffele G, et al: Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:718-730, 2010
13. US Food and Drug Administration: Talimogene lahaparepvec FDA briefing document BLA125518. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM444715.pdf
14. Carroll J: UPDATED: FDA review challenges Amgen on a questionable T-Vec study. FierceBiotech, Regulatory, April 27, 2015. http://www.fiercebiotech.com/story/fda-review-challenges-amgen-questionable-t-vec-study/2015-04-27